GLP-1 Medications and NAION: What Patients Should Know About Sudden Vision Loss

GLP-1 medications have become very common for treating type 2 diabetes and helping with weight loss. Many patients recognize names such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, and Trulicity. These medications can have important health benefits, especially for blood sugar control, weight management, and cardiovascular risk reduction. However, recent research has raised questions about whether some GLP-1 medications, especially semaglutide, may be associated with a higher risk of a rare but serious eye condition called NAION.

NAION stands for non-arteritic anterior ischemic optic neuropathy. It is sometimes described as an “eye stroke” because it happens when blood flow to the optic nerve is reduced. The optic nerve is the cable that carries visual information from the eye to the brain. When the optic nerve does not receive enough blood flow, sudden vision loss can occur.

Doctor explains NAION risk with Ozempic to a patient. Eye chart and image of an eye in the background. Text on symptoms and prevention.

What Is NAION?

NAION usually causes sudden, painless vision loss in one eye. Some patients notice a dark, gray, or missing area in their vision. Others wake up with blurred vision or a blind spot. The vision loss can be mild or severe, and unfortunately, it may be permanent.

Common risk factors for NAION include:

• Diabetes

• High blood pressure

• High cholesterol

• Sleep apnea

• Small or crowded optic nerves

• Smoking

• Cardiovascular disease

• Older age

These risk factors are important because many patients who take GLP-1 medications may already have diabetes, obesity, sleep apnea, or vascular risk factors that can also increase NAION risk.

Why Are GLP-1 Medications Being Discussed?

A 2024 study published in JAMA Ophthalmology found that patients prescribed semaglutide had a higher observed risk of NAION compared with patients using non-GLP-1 medications for diabetes or weight loss. The study found increased risk in both patients with type 2 diabetes and patients using semaglutide for overweight or obesity, but the authors noted that the study was observational and could not prove that semaglutide directly caused NAION.

Since then, additional studies have looked at this question with mixed results. A 2025 study in the American Journal of Ophthalmology did not find a significant increase in NAION or ischemic optic neuropathy risk in patients taking semaglutide or GLP-1 medications compared with diabetes or high-BMI control groups.

More recent research continues to suggest that there may be a signal worth paying attention to. A 2026 JAMA Ophthalmology study of U.S. veterans with type 2 diabetes found that semaglutide initiators had about a two-fold higher NAION risk compared with SGLT2 inhibitor initiators, although the absolute risk remained low.

In other words, the research is still developing. Some studies suggest an association, while others do not show a clear increased risk. At this time, patients should not panic, but they should be informed.

Does This Mean You Should Stop Taking a GLP-1?

No. Patients should not stop a GLP-1 medication without speaking with the prescribing doctor. These medications may provide major benefits for diabetes control, weight loss, heart health, and kidney health. For many patients, the benefits may outweigh the potential risks.

The goal is not to scare patients away from treatment. The goal is to make sure patients understand the warning signs of NAION and know when to seek urgent eye care.

Symptoms That Need Same-Day Eye Care

Call your eye doctor right away or seek urgent eye care if you experience:

• Sudden vision loss in one eye

• A new dark spot, gray area, or missing area in your vision

• Sudden blurry vision that does not clear

• Vision loss when waking up

• New loss of side vision or central vision

• Sudden change in color brightness between the two eyes

NAION is usually painless, so the absence of pain does not mean the problem is minor.

What Your Eye Doctor May Check

During an eye exam, your optometrist may evaluate the optic nerve and retina carefully. Testing may include:

• Dilated eye exam

• Optic nerve evaluation

• Retinal imaging

• OCT scan of the optic nerve and macula

• Visual field testing

• Blood pressure and medical history review

• Discussion of diabetes, sleep apnea, cholesterol, and cardiovascular risk factors

Your eye doctor may also coordinate care with your primary care doctor, endocrinologist, or prescribing provider if there are concerns.

Who Should Be More Careful?

Patients may need a more careful discussion if they have a history of:

• Previous NAION in one eye

• Significant optic nerve crowding

• Diabetes with vascular complications

• Sleep apnea, especially untreated sleep apnea

• High blood pressure or low nighttime blood pressure

• Cardiovascular disease

• Sudden unexplained vision loss in the past

This does not automatically mean a GLP-1 medication is unsafe, but it does mean the patient should have a personalized risk-benefit discussion with their medical provider.

The Bottom Line

GLP-1 medications are important treatments for many patients, but newer research has raised questions about a possible association between semaglutide and NAION. The risk appears to be rare, and the evidence is not fully settled. However, sudden vision loss should always be treated as urgent.

If you take a GLP-1 medication and notice sudden vision changes, do not wait to see if it improves. Contact your eye doctor immediately for same-day evaluation.

At OPT-ISM, we help patients monitor their eye health with comprehensive eye exams, retinal imaging, OCT testing, and careful evaluation of the optic nerve and retina.